Key Highlights
- CE reported third-quarter 2026 net sales of $2.556 billion, up 6% from $2.419 billion a year earlier.
- Adjusted EPS was $1.65 and GAAP diluted EPS from continuing operations was $0.68, versus an adjusted $1.34 and a GAAP loss of $12.39 in 2025.
- Operating EBITDA reached $548 million at a 21% margin, with adjusted EBIT of $367 million.
- Free Cash Flow was $461 million on Operating Cash Flow of $538 million.
- Full-year 2026 adjusted EPS is expected at about $6.00 to $6.25, with free cash flow of $750 million to $800 million.
Net Sales Rise 6% to $2.6 Billion as Adjusted EPS Climbs to $1.65
Celanese (NYSE:CE) reported third-quarter 2026 results on Nov 2, 2026 for the quarter ended Sep 30. Net sales were $2.556 billion, up 6% year over year but down 7% from the second quarter, which management described as expected moderation. Adjusted Earnings Per Share rose to $1.65 from $1.34, and GAAP diluted EPS from continuing operations was $0.68.
Operating profit was $198 million, adjusted EBIT was $367 million and operating EBITDA was $548 million, at margins of 8%, 14% and 21%. Net earnings attributable to the company were $74 million. The year-earlier quarter showed a net loss of $1.357 billion tied to a $1.1 billion non-cash Goodwill Impairment in Engineered Materials, so the GAAP comparison is distorted.
The company describes itself as a global chemical and specialty materials producer with 2025 net sales of $9.5 billion and more than 11,000 employees. It reports two segments, Engineered Materials and the Acetyl Chain.
Acetyl Chain Sales Jump 14% While Engineered Materials Leans on Medical and Electronics
Acetyl Chain net sales grew 14% to $1.209 billion, helped by pricing favorability and spot opportunities that outweighed modest Demand softness. Segment adjusted EBIT was $236 million and operating EBITDA was $301 million, a 25% margin. Sequentially, sales fell 9% as Supply chains normalized.
Engineered Materials sales slipped 1% to $1.368 billion, though the divested Micromax Business accounted for a 6% drag on the comparison. Growth in medical and electronics applications improved mix, offsetting weaker automotive demand, raw material Inflation and higher logistics costs. Adjusted EBIT was $209 million and operating EBITDA was $311 million, a 23% margin.
Cash Generation, Divestitures and Net Debt of $10.2 Billion Anchor the Deleveraging Push
Operating cash flow was $538 million and free cash flow was $461 million, bringing nine-month free cash flow to $604 million. Net debt (non-GAAP) fell to $10.183 billion from $10.643 billion at Jun 30, 2026, with total debt of $11.545 billion and cash of $1.362 billion.
The company signed a deal to sell an additional 19% of its Nutrinova food ingredients joint venture for about $152 million in cash, keeping an 11% stake, and expects it to close in the fourth quarter of 2026. It aims for about $1 billion of divestiture proceeds by the end of 2027 and about $650 million by year-end 2026. It also closed an acetate tow Facility in Belgium and formed a Partnership on plastic joint components for humanoid robots.
Guidance of $6.00 to $6.25 and a Dec 9 Investor Event Set the Next Markers
Management expects year-end seasonal moderation in both businesses and sees full-year 2026 adjusted EPS of about $6.00 to $6.25, while lifting its free cash flow outlook to $750 million to $800 million. It targets net debt to operating EBITDA of about 4.7 times at year-end and an adjusted tax rate of 8%. The company will hold an investor event on Dec 9, 2026 in Florence, Kentucky to detail strategy and growth priorities.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...